MALLINCKRODT PLC (MNK) Stock News

Endo board approves millions in bonuses to keep key execs amid Mallinckrodt merger

Mallinckrodt to merge with another drugmaker, Endo, in nearly $7B deal

Mallinckrodt, Endo Merger To Create Pharma Entity Valued At $7 Billion

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Mentions: NDOI

Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

Mallinckrodt, Endo Enter $6.7 Billion Merger Deal as Drug Makers Plan New US Listing

Mallinckrodt and Endo are set to merge in a cash-and-stock deal valued at $6.7 billion, with the dru

Endo agrees to merge with Mallinckrodt in deal valued at almost $7B

Mallinckrodt to take over Endo in deal valued at $6.7 billion

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and own nearly 50% of the combined company. Mallinckrodt shareholders will have a stake of slightly more than 50%.

Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal

Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in a deal valued at nearly $7 billion.

Mallinckrodt Pharma, Endo Reach Deal for $6.7 Billion Merger

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.

Mentions: NDOI

Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal

Under the terms of the agreement, Endo shareholders will get $80 million in cash and own 49.9% of the combined company on a pro forma basis, the companies said on Thursday. Mallinckrodt shareholders will own 50.1% of the combined company for an implied pro forma enterprise value of $6.7 billion. The combined company is expected to be listed on the New York Stock Exchange.

Drugmakers Mallinckrodt and Endo Are in Talks to Merge

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said.

Mentions: NDOI

What's Going On With Silence Therapeutics Stock Today?

Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial.

Mentions: AZN SLN

Mallinckrodt to discontinue StrataGraft due to slow uptake (OTCMKTS:MNKTQ)

Mallinckrodt (MNKTQ) said Monday it was discontinuing its regenerative skin tissue product StrataGraft, which is used for the treatment of thermal burns. The dr

Mallinckrodt emerges from bankruptcy (OTCMKTS:MNKTQ)

Mallinckrodt emerges from bankruptcy with reduced debt and new ownership structure, ready to focus on strategic initiatives and product launches.

UPDATE 1-Drugmaker Mallinckrodt emerges from bankruptcy

Drugmaker Mallinckrodt said on Tuesday it has emerged from bankruptcy and reduced its total funded debt by about $1.9 billion. Mallinckrodt, which won court approval for its bankruptcy plan last month, said it is moving ahead with ample liquidity to execute its strategic priorities. Pursuant to the bankruptcy plan, ownership of the company will now be handed over to its lenders and all its equity shares would cease to exist.

Drugmaker Mallinckrodt emerges from bankruptcy

Mallinckrodt, which won court approval for its bankruptcy plan last month, said it is moving ahead with ample liquidity to execute its strategic priorities. Pursuant to the bankruptcy plan, ownership of the company will now be handed over to its lenders and all its equity shares would cease to exist. Mallinckrodt, which makes branded and generic drugs, first filed for bankruptcy in 2020 to address its high debt load, litigation over its allegedly deceptive marketing of highly addictive generic opioids and drug pricing disputes.

Drugmaker Mallinckrodt emerges from bankruptcy

Drugmaker Mallinckrodt said on Tuesday it has completed its financial restructuring and emerged from bankruptcy.

Mallinckrodt sees emerging from Chapter 11 by end of year (MNKTQ)

Mallinckrodt has received approval from a US bankruptcy court for a reorganization plan that should allow it to emerge from Chapter 11 in Q4. Read more here.

Activist Hedge Funds Get Less Time to Disclose 5%-Plus Stakes Under SEC Rule

Activist hedge funds and other investors will have five days to disclose that they have taken on significant stakes in a company under final rules approved Tuesday by the Securities and Exchange Commission.

Trump Jurors Need Extra Protection in 2020 Election Case, Prosecutors Say

Prosecutors in the federal election obstruction case against Donald Trump asked the judge to take extra steps to protect jurors’ identities, arguing the former president uses social media as a “weapon of intimidation.”

KKR Considers $4.2 Billion Sale of European Car Park Operator Q-Park

KKR & Co. is considering a sale of Q-Park that may value the European car park operator at about €4 billion ($4.2 billion), including debt, according to people familiar with the matter.

Lithuanian Parliamentary Speaker to Visit Taiwan This Month

Lithuania’s parliamentary speaker will travel to Taiwan this month, becoming the nation’s highest-level official to visit the island — and potentially escalating simmering tensions between the European Union member state and China.

Housing Groups, Mortgage Lenders Urge Powell to Halt Fed Hikes

Three major housing-industry lobby groups called on Federal Reserve Chair Jerome Powell to refrain from raising interest rates any further and to pledge against selling mortgage bonds unless real estate financing stabilizes.

Mallinckrodt Approved to End Bankruptcy, Reduce Opioid Payments

Drugmaker Mallinckrodt Plc won court approval for a new debt-reduction plan that will slash about $1 billion from the sum the company must pay victims of America’s opioid epidemic.

Mentions: WFC

Mallinckrodt gets approval for restructuring, $1 billion cut to opioid settlement

Drugmaker Mallinckrodt on Tuesday received court approval for a bankruptcy plan that cuts $1 billion from the amount it must pay victims of the opioid crisis, cancels existing equity shares, and trims nearly $2 billion in other debt. U.S. Bankruptcy Judge John Dorsey approved the company's restructuring plan at a court hearing in Wilmington, Delaware. Mallinckrodt, which makes both branded and generic drugs, had first filed for bankruptcy in 2020 to address its high debt load, litigation over its allegedly deceptive marketing of highly addictive generic opioids and disputes over its drug pricing.

Mallinckrodt gets approval for restructuring, $1 billion cut to opioid settlement

Drugmaker Mallinckrodt on Tuesday received court approval for a bankruptcy plan that cuts $1 billion from the amount it must pay victims of the opioid crisis, cancels existing equity shares, and trims nearly $2 billion in other debt.

: Mallinckrodt bankruptcy plan gains approval from federal court

Prescription opioid maker Mallinckrodt on Tuesday gained federal court approval to erase more than $1 billion of payments intended for people with drug...

Japan’s Kokusai Electric Sets IPO Range Below Initial Guidance

KKR & Co. is set to raise up to ¥108 billion ($728 million) through the sale of shares in Japanese chip-equipment maker Kokusai Electric Corp., which set a price range for its initial public offering that was below its earlier guidance.

Mallinckrodt said to weigh sale of opioid business - WSJ

Mallinckrodt, which is in the middle of Chapter 11 bankruptcy, is said to be considering selling off its opioid business. Read more here.

Bankrupt drugmaker Mallinckrodt considers sale of opioid business - WSJ

Some investors, poised to take control through the company's ongoing bankruptcy proceedings, are suggesting Mallinckrodt break up its business units, the report said. Mallinckrodt did not immediately respond to a Reuters request for comment. The Ireland-based company filed for its second bankruptcy in the United States last month, with a restructuring plan that would cut $1 billion from what it owes to victims of the U.S. opioid crisis.

Bankrupt drugmaker Mallinckrodt considers sale of opioid business - WSJ

Bankrupt drugmaker Mallinckrodt is in talks with major investors about selling some or all of its business units, which could lead to its exit from the opioid business, the Wall Street Journal reported on Monday, citing people familiar with the discussions.

UPDATE 1-Bankrupt drugmaker Mallinckrodt considers sale of opioid business - WSJ

Bankrupt drugmaker Mallinckrodt is in talks with major investors about selling some or all of its business units, which could lead to its exit from the opioid business, the Wall Street Journal reported on Monday, citing people familiar with the discussions. Some investors, poised to take control through the company's ongoing bankruptcy proceedings, are suggesting Mallinckrodt break up its business units, the report said. Mallinckrodt did not immediately respond to a Reuters request for comment.

MALLINCKRODT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States. The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24. U.S.-based drugmakers Mallinckrodt and Viatris , UK-based Hikma Pharmaceuticals and Indian drugmaker Sun Pharmaceutical Industries confirmed on Thursday they began shipping their generic versions of the drug, which is also approved for a binge-eating disorder in adults.

Mallinckrodt gets access to $150M of new financing

A Delaware bankruptcy court has granted Mallinckrodt (MNKTQ) access to $150M of $250M of new commitments for financing from several creditors. Read more here.

Denmark’s Government Expects Financing Need to Decline in 2024

Denmark’s government said it will have a lower financing need next year as the Nordic country’s AAA economy is coming out of the inflation crisis better than feared.